New Methods for Evaluating Preventive Migraine Treatment
RecruitingNot applicableNCT07071506
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The study aims to test interactions between drug and placebo-responses in acute migraine treatment and to assess variation in adverse events according to treatment information provided. Using a clinical within-subjects, balanced placebo design, patients with chronic migraine will receive four treatment conditions in a randomized order.
Study details
- Official title
- New Methods for Evaluating Preventive Migraine Treatment
- Conditions
- Migraine
- Migraine With or Without Aura
- Headache Disorders
- Chronic Migraine, Headache
- Interventions
- Drug: Active drug for chronic migraine treatment.
- Drug: Placebo Subcutaneous injection
- Sponsor
- University of Aarhus
- Start date
- 2025-06-19
- Primary completion
- 2028-09
- Sex
- All
- Age range
- from 18 Years to 65 Years
- Results posted
- No results posted in this snapshot
- Countries
- Denmark
- Total sites listed
- 2
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: 1. Adults (18-65 years) 2. ≥ 1-year history of migraine with or without aura according to the International Classification of Headache Disorders (ICHD-3) diagnostic criteria 3. Known chronic migraine (headache occurring ≥ 15 days per month for \> 3 months, which on at least 8 days per month has the features of migraine headache) diagnosed before age 65 4. Eligibility for preventive migraine treatment 5. Ability to speak and read Danish Exclusion Criteria: 1. Use of onabotulinumtoxinA as preventive migraine treatment during the 4 months before inclusion 2. Use of other preventive migraine treatment except CGRP antagonists (However, participants are allowed to be on two stable preventive medication (antidepressant, calcium channel blockers, beta blockers or antiepileptic)- 2 months prior to inclusion until end of study), devices for migraine prevention such as transcranial magnetic stimulation and use of nerve blocks 3 months prior to inclusion 3. Use of opioid or barbiturate medications in the last four weeks before inclusion 4. Secondary headache disorders including medication overuse headache 5. Severe psychiatric, vascular disease, or known liver disease 6. Alcohol abuse or substance abuse 7. Current or planned pregnancy and lactation
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT07071506